Events & Presentations Upcoming Events No upcoming events at this time Past Events Leerink Conference Mar 11, 2026 at 8:00 AM EDT Click here for webcast Investor Presentations ARS Pharma Corporate Presentation ARS Pharma Corporate Presentation 4 MB Aug 9, 2024 neffy® FDA Approval Call Supporting Materials neffy FDA Approval Call (August 2024) 5.9 MB Mar 7, 2024 at 1:00 PM EST Neffy® Investor Day To view the webcast, click here Supporting Materials neffy investor day presentation (Mar 2024) 10.1 MB Scientific Presentations ACAAI 2023 Poster 12 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of 2.0 mg neffy to Pediatric Subjects with a History of Allergic Reactions 806.5 KB ACAAI 2023 Poster 18 Pharmacokinetics/Pharmacodynamics of Intranasal Epinephrine in Subjects with and without Upper Respiratory Infections 522.5 KB AAAAI 2023 Poster 28 Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB AAAAI 2023 Poster 9 Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB AAAAI 2023 Poster 8 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB AAAAI 2023 Poster 14 ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB AAAAI 2023 Poster 20 Use of Over-the-Counter Products to Treat Severe Allergic Reactions Before an Epinephrine Auto-Injection (EAI) Device: Results of a Patient/Caregiver Survey 745.7 KB ACAAI 2022 Poster 008 Epinephrine Via Needle-Free Device Would Be Administered Faster After Symptoms: Results of a Patient/Caregiver Survey 1.1 MB AAAAI 2022 Poster 008 Comparison of Pharmacokinetic Parameters and Intra-Blood Vessel Injection Rates Between Manual Intramuscular Injection and Epinephrine Auto-Injectors 333.1 KB Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3
Investor Presentations ARS Pharma Corporate Presentation ARS Pharma Corporate Presentation 4 MB Aug 9, 2024 neffy® FDA Approval Call Supporting Materials neffy FDA Approval Call (August 2024) 5.9 MB Mar 7, 2024 at 1:00 PM EST Neffy® Investor Day To view the webcast, click here Supporting Materials neffy investor day presentation (Mar 2024) 10.1 MB Scientific Presentations ACAAI 2023 Poster 12 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of 2.0 mg neffy to Pediatric Subjects with a History of Allergic Reactions 806.5 KB ACAAI 2023 Poster 18 Pharmacokinetics/Pharmacodynamics of Intranasal Epinephrine in Subjects with and without Upper Respiratory Infections 522.5 KB AAAAI 2023 Poster 28 Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB AAAAI 2023 Poster 9 Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB AAAAI 2023 Poster 8 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB AAAAI 2023 Poster 14 ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB AAAAI 2023 Poster 20 Use of Over-the-Counter Products to Treat Severe Allergic Reactions Before an Epinephrine Auto-Injection (EAI) Device: Results of a Patient/Caregiver Survey 745.7 KB ACAAI 2022 Poster 008 Epinephrine Via Needle-Free Device Would Be Administered Faster After Symptoms: Results of a Patient/Caregiver Survey 1.1 MB AAAAI 2022 Poster 008 Comparison of Pharmacokinetic Parameters and Intra-Blood Vessel Injection Rates Between Manual Intramuscular Injection and Epinephrine Auto-Injectors 333.1 KB Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3
A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of 2.0 mg neffy to Pediatric Subjects with a History of Allergic Reactions 806.5 KB
Pharmacokinetics/Pharmacodynamics of Intranasal Epinephrine in Subjects with and without Upper Respiratory Infections 522.5 KB
Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB
Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB
A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB
ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB
Use of Over-the-Counter Products to Treat Severe Allergic Reactions Before an Epinephrine Auto-Injection (EAI) Device: Results of a Patient/Caregiver Survey 745.7 KB
Epinephrine Via Needle-Free Device Would Be Administered Faster After Symptoms: Results of a Patient/Caregiver Survey 1.1 MB
Comparison of Pharmacokinetic Parameters and Intra-Blood Vessel Injection Rates Between Manual Intramuscular Injection and Epinephrine Auto-Injectors 333.1 KB
